Current Sirolimus News and Events

Current Sirolimus News and Events, Sirolimus News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 4 | 145 Results
Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential
The cover for issue 31 of Oncotarget features Figure 4, ''Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,'' by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival. (2020-10-21)

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial. (2020-10-14)

The Lancet journals: Papers at ESC Congress 2019
The following papers will be presented at the ESC Congress 2019, organised by the European Society of Cardiology in Paris and published simultaneously in either The Lancet or The Lancet Global Health journals. All papers are under embargo until the stated time. Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article. (2019-09-03)

Little-used drug combination may extend the lives of lung transplant patients
Median survival after lung transplant is less than six years. To see what might help lung transplant recipients live longer, University of Maryland School of Medicine researchers analyzed US lung transplant data, focused on immunosuppression regimes, and found a drug combination that appears to significantly extend patient survival. (2019-08-28)

ACTG presents new research on HIV and TB, co-morbidities, treatment, and cure at CROI 2019
The AIDS Clinical Trials Group (ACTG), the world's largest and longest-established HIV research network, funded by NIAID at the U.S. NIH, will make 11 oral and 19 poster presentations at CROI 2019 (Seattle, March 4-7). Several have the potential to influence clinical practice and guidelines for care. (2019-02-26)

Potential cognitive effects of targeted drugs in children may be reversible with therapy
Young mice that received molecularly targeted therapies used to treat brain cancer in human patients sustained cognitive and behavioral deficits, but the deficits were largely reversible through environmental stimulation and physical exercise. The study suggests that pediatric brain cancer patients may experience similar side effects of molecularly targeted therapies, and may benefit from efforts to remediate any cognitive deficits. (2018-03-20)

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. (2018-01-16)

New guidelines issued for diagnosis and care of LAM, a rare lung disease
The American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) have published additional clinical practice guidelines regarding four specific questions related to the diagnosis of lymphangioleiomyomatosis (LAM) and management of pneumothoraces in patients with LAM. (2017-11-15)

One year results from the REDUCE trial reported at TCT 2017
Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. (2017-11-01)

Rapamycin treatment prevents crippling abnormal bone formation after severe limb injuries
Individuals with severe injuries to their extremities often develop abnormal extra-skeletal bone in damaged or healing tissue, known as heterotopic ossification (HO). This post-traumatic abnormal wound healing can interfere with recovery, causing chronic pain, reduced mobility, and impaired prosthetic limb function. A new study describes a potential treatment breakthrough. Rapamycin, an FDA-approved drug already on the market, was found to dramatically reduce the presence of HO in rats, suggesting it has potential to become the first effective treatment to prevent HO. (2017-10-11)

What are risk factors for melanoma in kidney transplant recipients?
Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by JAMA Dermatology. (2017-07-26)

UC research examines lung cell turnover as risk factor & target for treatment of influenza pneumonia
Most of the 500,000 annual deaths worldwide from influenza are due to influenza pneumonia. Understanding how the transition to pneumonia occurs could shed light on interventions that could reduce that number. Research from the University of Cincinnati takes a different approach to how flu spreads through the lungs by focusing on how resistant or susceptible cells lining the airway are to viral infection. (2017-07-24)

Results with new bioresorbable stent (BRS) technologies reported at EuroPCR 2017
Paris, France: Promising results were reported in late-breaking trials with novel bioresorbable stent technologies at EuroPCR 2017, paving the way for ongoing developments in stents that are dissolved or reabsorbed after achieving vessel expansion in percutaneous coronary intervention procedures. (2017-05-19)

Northwell Health's Feinstein Institute discovers cancer treatment for transplant patients
Kenar D. Jhaveri, M.D., and Richard Barnett, M.D., Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the prestigious New England Journal of Medicine, which profiles a novel drug combination with the potential to help prevent rejection of a donor kidney in transplant patients undergoing cancer treatment. (2017-01-18)

Results from PRISON IV presented at TCT & published in JACC: Cardiovascular Interventions
Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES. (2016-11-07)

TCT 2016 first reports examine potential for novel bioresorbable stent technologies
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) featured a number of first report investigations on novel stents that could become the next generation of bioresorbable stents in patients. (2016-10-31)

Results from REVELUTION reported at TCT & published in JACC: Cardiovascular Interventions
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition. (2016-10-31)

Results from the BIO-RESORT trial presented at TCT 2016 and published in The Lancet
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes. (2016-10-30)

Common cause for complications after kidney transplantation identified
The BK polyomavirus often causes complications after kidney transplantation. The research group of Professor Hans H. Hirsch from the Department of Biomedicine at the University of Basel has now been able to show, that the immunosuppressive drug Tacrolimus directly activates the replication of the virus and could thus be responsible for these complications. The American Journal of Transplantation has published the study. (2015-11-23)

Study: Sirolimus is effective, safe for treatment-resistant autoimmune blood conditions
The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology. This treatment is particularly effective in children with autoimmune lymphoproliferative syndrome, a chronic genetic disorder characterized by the buildup of white blood cells in the organs. (2015-10-26)

A 'profound' success in treating children and young adults with rare blood disorders
Hematology researchers have safely and effectively treated children and young adults for autoimmune blood disorders in a multicenter clinical trial. In children with one of those conditions, autoimmune lymphoproliferative syndrome, all the patients showed a durable, complete response, with normal blood cell counts and rapid improvements, a result the study team called 'profound.' (2015-10-26)

Drugs commonly used in kidney transplant patients not as effective as previously thought
Kidney transplants saves lives and dramatically improve quality of life, but transplant recipients often must take dozens of pills a day to keep their new kidney functioning and prevent complications. Now, three new studies led by The Ottawa Hospital and the University of Ottawa show that three of these drugs are not nearly as effective as previously thought and may have serious side-effects. The results are expected to change medical practice around the world. (2015-10-22)

Data presented at TCT will show whether the 'dissapearing' stent is a breakthrough in PCI
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. (2015-09-28)

CRF announces press conference schedule for TCT 2015
The Cardiovascular Research Foundation has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics 2015 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California. (2015-09-22)

Recruitment of leukocytes is a hallmark of stent thrombosis
Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis. (2015-08-30)

Announcing the TCT 2015 late-breaking trials and first report investigations
CRF has announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics 2015 scientific symposium. From an unprecedented number of high-quality submissions, TCT has chosen 20 studies that will impact the care of patients and how physicians think about cardiovascular disease. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place Oct. 11-15, 2015, at the Moscone Center in San Francisco, Calif. (2015-08-22)

The Lancet: European Society of Cardiology Congress 2014 media alert
The Lancet is pleased to announce that two papers will be published to coincide with presentation at the ESC Congress 2014, taking place in Barcelona, Spain, Aug. 30-Sept. 3, 2014. (2014-09-02)

CRF announces late-breaking trials and first report investigations for TCT 2014
The Cardiovascular Research Foundation has announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place Sept. 13 - 17, 2014 at the Walter E. Washington Convention Center in Washington, DC. (2014-08-01)

New therapeutic combination to slow resistant sarcomas
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer. (2014-07-10)

Patients with rare lung disease face agonizing treatment dilemma
The drug sirolimus can slow progression of the lung disease LAM, while also causing potentially fatal complications in lung transplant patients. But research suggests a drug similar to sirolimus may be safe for LAM patients waiting for transplants. (2014-04-17)

Transplant drugs may help wipe out persistent HIV infections
New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS. (2014-04-03)

Study shows low rate of late lumen loss with bioresorbable DESolve device
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today. (2013-05-21)

Biodegradable stent proves non-inferior to drug-eluting stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today. (2013-05-21)

Intractable seizures halted with experimental treatment for rare pediatric 'Pretzel syndrome'
With a better understanding of underlying mechanisms that cause a rare neurodevelopmental disorder in the Old Order Mennonite population, referred to as Pretzel syndrome, a new study reports that five children were successfully treated with a drug that modifies the disease process, minimizing seizures and improving receptive language. The study, by researchers including experts from the Perelman School of Medicine at the University of Pennsylvania, appears in the journal Science Translational Medicine. (2013-04-24)

Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
Dana-Farber researchers found an experimental drug combination for preventing graft-vs.-host disease was not significantly better than the standard regimen of care, but that the new combination could provide an alternative that could be preferable in certain scenarios. (2012-12-10)

CHOP experts describe research in pediatric heart disease
Physician-researchers from The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions. They described racial disparities in risk factors for sudden cardiac death, imaging modalities and novel approaches to assessing cardiac anomalies, ventricular assist device use, changes in immunosuppressive drugs after pediatric heart transplant, and many other topics. (2012-11-08)

Dual antiplatelet therapy may be important for patients who have drug-eluting stents implanted
Research published in the Lancet examines the long-term effects on patients of medical devices - known as drug-eluting stents - implanted to widen blood vessels. (2012-08-27)

The PROTECT study
Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012. (2012-08-27)

Use of newer-generation drug-releasing stent results in lower rate of adverse cardiac events
Compared with a bare-metal stent, the use of a stent with a biodegradable polymer that releases the drug biolimus resulted in a lower rate of major adverse cardiac events at 1 year among patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack) undergoing primary percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). (2012-08-21)

Grapefruit juice lets patients take lower dose of cancer drug
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication. (2012-08-07)

Page 1 of 4 | 145 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.